

Yiyu Dong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4976953/publications.pdf>

Version: 2024-02-01

23
papers

1,257
citations

471509

17
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

2766
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Genomic Analysis of H ¹ /4rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	16.8	195
2	The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. <i>Cell Reports</i> , 2017, 18, 2893-2906.	6.4	153
3	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	12.8	140
4	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. <i>Nature Communications</i> , 2017, 8, 16078.	12.8	135
5	PUMA and BIM Are Required for Oncogene Inactivationâ€“Induced Apoptosis. <i>Science Signaling</i> , 2013, 6, ra20.	3.6	107
6	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. <i>Journal of Clinical Investigation</i> , 2016, 126, 3526-3540.	8.2	82
7	Synthetic Lethality through Combined Notchâ€“Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer. <i>Cancer Research</i> , 2010, 70, 5465-5474.	0.9	64
8	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	12.8	61
9	¹³⁷ Np63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. <i>Cell Reports</i> , 2017, 21, 2926-2939.	6.4	61
10	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	12.8	37
11	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	3.1	31
12	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	6.0	31
13	Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. <i>Cell Research</i> , 2014, 24, 1354-1366.	12.0	29
14	Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models. <i>Cancer Research</i> , 2019, 79, 242-250.	0.9	27
15	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. <i>Biomaterials</i> , 2021, 269, 120630.	11.4	27
16	SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. <i>Nature Cancer</i> , 2022, 3, 188-202.	13.2	26
17	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	3.3	21
18	Mitochondrial genotype remodels the metabolic and microenvironmental landscape of H ¹ /4rthle cell carcinoma. <i>Science Advances</i> , 2022, 8, .	10.3	15

#	ARTICLE	IF	CITATIONS
19	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	3.0	9
20	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 382-394.	4.1	6
21	Comparing surgical tissue versus biopsy tissue in the development of a clear cell renal cell carcinoma xenograft model. <i>Journal of Clinical Oncology</i> , 2016, 34, 519-519.	1.6	0
22	Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e16102-e16102.	1.6	0
23	Patient derived xenografts of upper tract urothelial carcinoma: A potential tool for personalized medicine. <i>Journal of Clinical Oncology</i> , 2017, 35, 344-344.	1.6	0